Platelet-driven leukotriene C4-mediated airway inflammation in mice is aspirin-sensitive and depends on t prostanoid receptors

Journal of Immunology

Volumn 194, Issue 11, 2015, Pages 5061-5068

  Liu, Tao ^a,b   Garofalo, Denise ^b   Feng, Chunli ^b   Lai, Juying ^b   Katz, Howard ^a,b   Laidlaw, Tanya M ^a,b,c   Boyce, Joshua A ^a,b,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c Jeff and Penny Vinik Center for Allergic Disease Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; INTERCELLULAR ADHESION MOLECULE 1; LEUKOTRIENE C4; PROSTANOID RECEPTOR; T PROSTANOID RECEPTOR; THROMBOXANE A2; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; ALLERGEN; CYSTEINE; CYSTEINYL-LEUKOTRIENE; LEUKOTRIENE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; OVALBUMIN; PROSTAGLANDIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOCRINE EFFECT; CONTROLLED STUDY; DRUG SENSITIVITY; EOSINOPHIL COUNT; EOSINOPHILIA; IN VIVO STUDY; LUNG LAVAGE; MOUSE; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY TRACT INFLAMMATION; THROMBOCYTE; THROMBOCYTE ACTIVATION; UPREGULATION; ANIMAL; ASTHMA; BIOSYNTHESIS; BLOOD; BONE MARROW TRANSPLANTATION; BRONCHOALVEOLAR LAVAGE FLUID; C57BL MOUSE; CYTOLOGY; GENETICS; IMMUNOLOGY; INFLAMMATION; KNOCKOUT MOUSE; LUNG; METABOLISM;

ALLERGENS; ANIMALS; ASPIRIN; ASTHMA; BLOOD PLATELETS; BONE MARROW TRANSPLANTATION; BRONCHOALVEOLAR LAVAGE FLUID; CYSTEINE; EOSINOPHILIA; INFLAMMATION; INTERCELLULAR ADHESION MOLECULE-1; LEUKOTRIENE ANTAGONISTS; LEUKOTRIENE C4; LEUKOTRIENES; LUNG; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OVALBUMIN; PLATELET ACTIVATION; RECEPTORS, PROSTAGLANDIN; THROMBOXANE A2; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84929630133     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1402959     Document Type: Article

References (43)

1. Lam, B. K., J. F. Penrose, G. J. Freeman, and K. F. Austen. 1994. Expression cloning of a cDNA for human leukotriene C4 synthase, an integral membrane protein conjugating reduced glutathione to leukotriene A4. Proc. Natl. Acad. Sci. USA 91: 7663-7667.
2. Carter, B. Z., Z. Z. Shi, R. Barrios, and M. W. Lieberman. 1998. Gammaglutamyl leukotrienase, a gamma-glutamyl transpeptidase gene family member, is expressed primarily in spleen. J. Biol. Chem. 273: 28277-28285.
3. Lee, C. W., R. A. Lewis, E. J. Corey, and K. F. Austen. 1983. Conversion of leukotriene D4 to leukotriene E4 by a dipeptidase released from the specific granule of human polymorphonuclear leucocytes. Immunology 48: 27-35.
4. Austen, K. F., A. Maekawa, Y. Kanaoka, and J. A. Boyce. 2009. The leukotriene E4 puzzle: finding the missing pieces and revealing the pathobiologic implications. J. Allergy Clin. Immunol. 124: 406-414, quiz 415-416.
5. Weiss, J. W., J. M. Drazen, N. Coles, E. R. McFadden, Jr., P. F. Weller, E. J. Corey, R. A. Lewis, and K. F. Austen. 1982. Bronchoconstrictor effects of leukotriene C in humans. Science 216: 196-198.
6. Soter, N. A., R. A. Lewis, E. J. Corey, and K. F. Austen. 1983. Local effects of synthetic leukotrienes (LTC4, LTD4, LTE4, and LTB4) in human skin. J. Invest. Dermatol. 80: 115-119.
7. Gauvreau, G. M., K. N. Parameswaran, R. M. Watson, and P. M. O'Byrne. 2001. Inhaled leukotriene E(4), but not leukotriene D(4), increased airway inflammatory cells in subjects with atopic asthma. Am. J. Respir. Crit. Care Med. 164: 1495-1500.
8. Israel, E., J. Cohn, L. Dubé, and J. M. Drazen, Zileuton Clinical Trial Group. 1996. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. JAMA 275: 931-936.
9. Di Gennaro, A., D. Wagsäter, M. I. Mäyränpää, A. Gabrielsen, J. Swedenborg, A. Hamsten, B. Samuelsson, P. Eriksson, and J. Z. Haeggström. 2010. Increased expression of leukotriene C4 synthase and predominant formation of cysteinylleukotrienes in human abdominal aortic aneurysm. Proc. Natl. Acad. Sci. USA 107: 21093-21097.
10. Lynch, K. R., G. P. O'Neill, Q. Liu, D. S. Im, N. Sawyer, K. M. Metters, N. Coulombe, M. Abramovitz, D. J. Figueroa, Z. Zeng, et al. 1999. Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature 399: 789-793.
11. Heise, C. E., B. F. O'Dowd, D. J. Figueroa, N. Sawyer, T. Nguyen, D. S. Im, R. Stocco, J. N. Bellefeuille, M. Abramovitz, R. Cheng, et al. 2000. Characterization of the human cysteinyl leukotriene 2 receptor. J. Biol. Chem. 275: 30531-30536.
12. Kanaoka, Y., A. Maekawa, and K. F. Austen. 2013. Identification of GPR99 protein as a potential third cysteinyl leukotriene receptor with a preference for leukotriene E4 ligand. J. Biol. Chem. 288: 10967-10972.
13. Barrett, N. A., O. M. Rahman, J. M. Fernandez, M. W. Parsons, W. Xing, K. F. Austen, and Y. Kanaoka. 2011. Dectin-2 mediates Th2 immunity through the generation of cysteinyl leukotrienes. J. Exp. Med. 208: 593-604.
14. Kim, D. C., F. I. Hsu, N. A. Barrett, D. S. Friend, R. Grenningloh, I. C. Ho, A. Al-Garawi, J. M. Lora, B. K. Lam, K. F. Austen, and Y. Kanaoka. 2006. Cysteinyl leukotrienes regulate Th2 cell-dependent pulmonary inflammation. J. Immunol. 176: 4440-4448.
15. Beller, T. C., A. Maekawa, D. S. Friend, K. F. Austen, and Y. Kanaoka. 2004. Targeted gene disruption reveals the role of the cysteinyl leukotriene 2 receptor in increased vascular permeability and in bleomycin-induced pulmonary fibrosis in mice. J. Biol. Chem. 279: 46129-46134.
16. Maekawa, A., K. F. Austen, and Y. Kanaoka. 2002. Targeted gene disruption reveals the role of cysteinyl leukotriene 1 receptor in the enhanced vascular permeability of mice undergoing acute inflammatory responses. J. Biol. Chem. 277: 20820-20824.
17. Israel, E., P. S. Chervinsky, B. Friedman, J. Van Bavel, C. S. Skalky, A. F. Ghannam, S. R. Bird, and J. M. Edelman. 2002. Effects of montelukast and beclomethasone on airway function and asthma control. J. Allergy Clin. Immunol. 110: 847-854.
18. Johansson, M. W., S. T. Han, K. A. Gunderson, W. W. Busse, N. N. Jarjour, and D. F. Mosher. 2012. Platelet activation, P-selectin, and eosinophil b1-integrin activation in asthma. Am. J. Respir. Crit. Care Med. 185: 498-507.
19. Laidlaw, T. M., M. S. Kidder, N. Bhattacharyya, W. Xing, S. Shen, G. L. Milne, M. C. Castells, H. Chhay, and J. A. Boyce. 2012. Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by plateletadherent leukocytes. Blood 119: 3790-3798.
20. Pitchford, S. C., S. Momi, S. Giannini, L. Casali, D. Spina, C. P. Page, and P. Gresele. 2005. Platelet P-selectin is required for pulmonary eosinophil and lymphocyte recruitment in a murine model of allergic inflammation. Blood 105: 2074-2081.
21. Hasegawa, S., T. Ichiyama, K. Hashimoto, Y. Suzuki, R. Hirano, R. Fukano, and S. Furukawa. 2010. Functional expression of cysteinyl leukotriene receptors on human platelets. Platelets 21: 253-259.
22. Cummings, H. E., T. Liu, C. Feng, T. M. Laidlaw, P. B. Conley, Y. Kanaoka, and J. A. Boyce. 2013. Cutting edge: leukotriene C4 activates mouse platelets in plasma exclusively through the type 2 cysteinyl leukotriene receptor. J. Immunol. 191: 5807-5810.
23. Thomas, D. W., and T. M. Coffman. 1998. A genetic approach for studying the role of thromboxane A2 in the kidney. Kidney Int. Suppl. 67: S84-S87.
24. Paruchuri, S., H. Tashimo, C. Feng, A. Maekawa, W. Xing, Y. Jiang, Y. Kanaoka, P. Conley, and J. A. Boyce. 2009. Leukotriene E4-induced pulmonary inflammation is mediated by the P2Y12 receptor. J. Exp. Med. 206: 2543-2555.
25. Liu, T., T. M. Laidlaw, H. R. Katz, and J. A. Boyce. 2013. Prostaglandin E2 deficiency causes a phenotype of aspirin sensitivity that depends on platelets and cysteinyl leukotrienes. Proc. Natl. Acad. Sci. U. S. A. 110: 16987-16992.
26. Laidlaw, T. M., and J. A. Boyce. 2013. Pathogenesis of aspirin-exacerbated respiratory disease and reactions. Immunol. Allergy Clin. North Am. 33: 195-210.
27. White, A., E. Ludington, P. Mehra, D. D. Stevenson, and R. A. Simon. 2006. Effect of leukotriene modifier drugs on the safety of oral aspirin challenges. Ann. Allergy Asthma Immunol. 97: 688-693.
28. Honda, K., M. Arima, G. Cheng, S. Taki, H. Hirata, F. Eda, F. Fukushima, B. Yamaguchi, M. Hatano, T. Tokuhisa, and T. Fukuda. 2003. Prostaglandin D2 reinforces Th2 type inflammatory responses of airways to low-dose antigen through bronchial expression of macrophage-derived chemokine. J. Exp. Med. 198: 533-543.
29. Cummings, H. E., T. Liu, C. Feng, T. M. Laidlaw, P. B. Conley, Y. Kanaoka, and J. A. Boyce. 2013. Cutting edge: leukotriene C4 activates mouse platelets in plasma exclusively through the type 2 cysteinyl leukotriene receptor. J. Immunol. 191: 4926-4939.
30. Pitchford, S. C., S. Momi, S. Baglioni, L. Casali, S. Giannini, R. Rossi, C. P. Page, and P. Gresele. 2008. Allergen induces the migration of platelets to lung tissue in allergic asthma. Am. J. Respir. Crit. Care Med. 177: 604-612.
31. De Caterina, R., D. Giannessi,W. Bernini, P. Gazzetti, C. Michelassi, A. L'Abbate, L. Donato, P. Patrignani, P. Filabozzi, and C. Patrono. 1985. Low-dose aspirin in patients recovering from myocardial infarction. Evidence for a selective inhibition of thromboxane-related platelet function. Eur. Heart J. 6: 409-417.
32. Szczeklik, A., R. J. Gryglewski, E. Olszewski, A. Dembińska-Kiec, and G. Czerniawska-Mysik. 1977. Aspirin-sensitive asthma: the effect of aspirin on the release of prostaglandins from nasal polyps. Pharmacol. Res. Commun. 9: 415-425.
33. Sestini, P., L. Armetti, G. Gambaro, M. G. Pieroni, R. M. Refini, A. Sala, A. Vaghi, G. C. Folco, S. Bianco, and M. Robuschi. 1996. Inhaled PGE2 prevents aspirin-induced bronchoconstriction and urinary LTE4 excretion in aspirinsensitive asthma. Am. J. Respir. Crit. Care Med. 153: 572-575.
34. Picado, C., J. C. Fernandez-Morata, M. Juan, J. Roca-Ferrer, M. Fuentes, A. Xaubet, and J. Mullol. 1999. Cyclooxygenase-2 mRNA is downexpressed in nasal polyps from aspirin-sensitive asthmatics. Am. J. Respir. Crit. Care Med. 160: 291-296.
35. Berges-Gimeno, M. P., R. A. Simon, and D. D. Stevenson. 2003. Long-term treatment with aspirin desensitization in asthmatic patients with aspirinexacerbated respiratory disease. J. Allergy Clin. Immunol. 111: 180-186.
36. Zarbock, A., K. Singbartl, and K. Ley. 2006. Complete reversal of acid-induced acute lung injury by blocking of platelet-neutrophil aggregation. J. Clin. Invest. 116: 3211-3219.
37. Liu, T., T. M. Laidlaw, C. Feng, W. Xing, S. Shen, G. L. Milne, and J. A. Boyce. 2012. Prostaglandin E2 deficiency uncovers a dominant role for thromboxane A2 in house dust mite-induced allergic pulmonary inflammation. Proc. Natl. Acad. Sci. USA 109: 12692-12697.
38. Yuan, Q., K. F. Austen, D. S. Friend, M. Heidtman, and J. A. Boyce. 1997. Human peripheral blood eosinophils express a functional c-kit receptor for stem cell factor that stimulates very late antigen 4 (VLA-4)-mediated cell adhesion to fibronectin and vascular cell adhesion molecule 1 (VCAM-1). J. Exp. Med. 186: 313-323.
39. Tamaoki, J., M. Kondo, J. Nakata, Y. Nagano, K. Isono, and A. Nagai. 2000. Effect of a thromboxane A(2) antagonist on sputum production and its physicochemical properties in patients with mild to moderate asthma. Chest 118: 73-79.
40. Hoshino, M., J. Sim, K. Shimizu, H. Nakayama, and A. Koya. 1999. Effect of AA-2414, a thromboxane A2 receptor antagonist, on airway inflammation in subjects with asthma. J. Allergy Clin. Immunol. 103: 1054-1061.
41. Cahill, K. N., J. C. Bensko, J. A. Boyce, and T. M. Laidlaw. 2015. Prostaglandin D: a dominant mediator of aspirin-exacerbated respiratory disease. J. Allergy Clin. Immunol. 135: 245-252.
42. Ingelsson, E., L. Yin, and M. Bäck. 2012. Nationwide cohort study of the leukotriene receptor antagonist montelukast and incident or recurrent cardiovascular disease. J. Allergy Clin. Immunol. 129: 702-707, e2.
43. Ni, N. C., D. Yan, L. L. Ballantyne, A. Barajas-Espinosa, T. St Amand, D. A. Pratt, and C. D. Funk. 2011. A selective cysteinyl leukotriene receptor 2 antagonist blocks myocardial ischemia/reperfusion injury and vascular permeability in mice. J. Pharmacol. Exp. Ther. 339: 768-778.